SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 29, 2004
Sirna Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
Delaware | | 0-27914 | | 34-1697351 |
(State or other jurisdiction of incorporation) | | (Commission File No.) | | (I.R.S. Employer Identification Number |
2950 Wilderness Place Boulder, Colorado 80301
(Address of principal executive offices)
Registrant’s telephone number, including area code: (303) 449-6500
N/A
(Former name or former address, if changed since last report.)
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
99.1 Press Release issued by the Company on July 29, 2004.
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
The following information is furnished pursuant to Item 12. “Results of Operations and Financial Condition.”
On July 29, 2004, Sirna Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2004. A copy of the press release is furnished as Exhibit 99.1 to this report. This Form 8-K and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 29, 2004
SIRNA THERAPEUTICS, INC.
(Registrant)
| | | | | | |
| | | | | |
| By: | | /s/ Howard W. Robin | | | | |
| | |
| | | | |
| Name: | | Howard W. Robin | | | | |
| Title: | | President and Chief Executive Officer | | | | |
3
EXHIBIT INDEX
| | |
Exhibit No.
| | Description of Exhibit
|
| |
| 99.1 | | Press Release issued by the Company on July 29, 2004. |
4
